Credit Suisse Ag Eq Rx, Inc. Transaction History

Credit Suisse Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$1.66 - $2.31 $25,768 - $35,858	-15,523 Reduced 7.43%	193,294 $429,000
Q2 2023 Aug 11, 2023	BUY	$1.61 - $1.96 $153,072 - $186,348	95,076 Added 83.59%	208,817 $388,000
Q1 2023 May 10, 2023	BUY	$1.8 - $2.83 $64 - $101	36 Added 0.03%	113,741 $220,000
Q4 2022 Feb 13, 2023	BUY	$2.05 - $5.5 $28,306 - $75,944	13,808 Added 13.82%	113,705 $279,000
Q3 2022 Nov 10, 2022	BUY	$0.94 - $5.99 $1,019 - $6,499	1,085 Added 1.1%	99,897 $495,000
Q2 2022 Aug 12, 2022	BUY	$3.2 - $5.69 $316,198 - $562,240	98,812 New	98,812 $464,000

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.